Publications

1. Paulden, M.  O’Mahoney, JF.,  McCabe, C., Discounting the recommendations of the second panel on cost effectiveness in health and medicine. PharmacoEconomics 2016. (Epub)
2.

McCabe, C., Sipp, D. Undertested and over-priced: Japan issues first conditional approval of stem cell product. Cell stem cell. 2016; 18(4):436-7

3. Daley, GQ., Hyun, I., Apperley, JF., et al. Setting global standards for stem cell research and clinical translation. The 2016 ISSCR guidelines. Stem Cell Reports 2016
4.

Bartlett, John MS; Bayani, Jane; Marshall, Andrea et al. Comparing Breast Cancer Multi-parameter   Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. Journal of the National Cancer Institute. 2016; 108(9): djw050

5.

Wallner, K., Shapiro, AJM., Senior, PA., McCabe, C., Cost effectiveness and value of information analysis of islet cell transplant in ‘untable’ Type 1 Diabetes Mellitus. BMC Endocrine Disorders, 2016; 16(1).

6.

McCabe C. Fell, G. Paul, A. Paulden, M.  CDF 2.0: a missed opportunity. PharmacoEconomics 22(1): 2016 (epub)

7.

McCabe CJ. A review of “The new drug reimbursement game: a regulators guide to playing and winning.” Applied Health Economics and Health Policy.  2016; 1:

8.

Stein, RC. Dunn, J., Bartlett, J. et al OPTIMA-prelim:a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technology Assessment. 2016; 20(10)

9.

Wright-Hughes, A. Graham, E., Farrin, A. et al. Self-Harm intervention famly therapy (SHIFT): a study protocol for a randomised controlled trial of family therapy… Trials. 2015; 16(1):501

10.

Bubela T. McCabe, C. Archibald, P. et al Bringing regenerative medicines to clinic: the future for regulation and reimbursement. Regenerative Medicine. 2015; 10(7):897-911

11.

Kharroubi, SA; Edlin, R; Meads, D; Browne, C; Brown, J; McCabe, C. Use of Bayesian Markov Chain Monte Carlo Methods to Estimate EQ-5D Utility Scores from EORTC QLQ Data in Myeloma for Use in Cost-Effectiveness Analysis Medical Decision Making. 2015; 33(3):351-360

12. Paulden M, Stafinski T, Menon, D, McCabe C.Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework.  PharmacoEconomics. 2015; 33(3):255-269
13.

Bubela, T. McCabe, C. Value-engineered translation: developing biotherapeutics that align with health system needs. American Journal of Managed Care:Evidence-based Diabetes Management 2014. Available at: http://www.ajmc.com/publications/evidence-based-diabetes-management/2014/july-august-2014/value-engineered-translation-developing-biotherapeutics-that-align-with-health-system-needs

14.

Coy, NN., Brown, S. Bosworth, A. et al. The SWITCH study protocol BMC Muskuloskeletal Disorders. 2014, 15(1): 452

15.

Stafinski T, McCabe C, Menon D. Determining social values for resource allocation decision-making in cancer care: a Canadian experiment. Journal of Cancer Policy, 2014. 2(3), 81-88.

16.

Paulden M, O’Mahony JF, Culyer AJ, McCabe C. Nice's Proposed Value-Based Assessment of Health Technologies: Concerns of Inconsistent Consideration of Social Values. Value in Health, 2014. 17(7), 330.

17.

Paulden M, O’Mahony JF, Culyer A, McCabe C. Objectivity and Equity: Clarity Required. A Response to Hill and Olson. PharmacoEconomics, 2014. 32(12), 1249-1250.

18.

McCabe C, Husereau D. Personalized Medicine and Health Care Policy: From Science to Value. Genome Canada, 2014.

19.

Paulden M, O’Mahony JF, Culyer A, McCabe C. Objectivity and Equity: Clarity Required. A Response to Hill and Olson. PharmacoEconomics, 2014. 32(12), 1249-1250.

20.

Paulden, M, O’Mahony JF, Culyer A, McCabe C. Some Inconsistencies in NICE’s Consideration of Social Values. PharmacoEconomics, 2014.

21.

McCabe C, Husereau D. Personalized Medicine and Health Care Policy: From Science to Value. Genome Canada, 2014.

22.

Meads D, McCabe C, Hulme C, Edlin R, Kharroubi S, Browne C, Ford H, Dunn J, Marshall A. Cost-Utility of Cancer Therapies–the 'Cost' of Different Utility Generation Strategies. Value in Health, 2014. 17(7), 327.

23.

Paulden M, O’Mahony JF, Culyer AJ, McCabe C. NICE's Proposed Value-Based Assessment of Health Technologies: Concerns of Inconsistent Consideration of Social Values. Value in Health, 2014. 17(7), 330.

24.

Paulden M, McCabe C, Karnon J. Achieving allocative efficiency in healthcare: nice in theory, not so NICE in Practice?  PharmacoEconomics, 2014. 32(4), 315-318. 

25.

Longo R, Baxter P, Hall P, Hewison J, Afshar M, Hall G, McCabe C. Methods for identifying the cost-effective case definition cut-off for sequential monitoring tests: an extension of Phelps and Mushlin. PharmacoEconomics, 2014. 32(4), 327-334.

26.

Edlin R, Hall P, Wallner K, McCabe C. Sharing Risk between Payer and Provider by Leasing Health Technologies: An Affordable and Effective Reimbursement Strategy for Innovative Technologies? Value in Health 2014, 17(4) 438-444.

27.

Bubela T, McCabe C Value Engineered Translation for stem cells: meeting the needs of health systems. World Stem Cell Report. Stem cells and development 2013; 22(S1):89-93

28

Caulfield T, Evans J, McGuire A, McCabe C, et al Reflections on the cost of low cost whole genome screening: framing the health policy debate. PLOS Biology 2013 DOI: 10.1371/journal.pbio.1001699

29.

McCabe C, Edlin P, Hall P. Navigating time and uncertainty in health technology appraisal: would a map help? PharmacoEconomics 2013 31(9);731-737

30.

McCabe C, Edlin R, Meads D, Browne C, Kharoubi S. Constructing indirect utility models: some observations on principles ad practice of mapping to obtain health state utilities. PharmacoEconomics 2013; 31(8):635-641

31.

Hall P, and McCabe C. What evidence is there for the reimbursement of personalised medicine. PharmacoEconomics. 31(1):1-3

32.

Edlin R, Round J, McCabe C, Sculpher M, Claxton K, Cookson R. Understanding Harris’ understanding of CEA: is cost effective resource allocation undone? Journal of Health Services Research and Policy. 2013;18(1):34-39